CTIS2024-514319-85-00招募中1 期
Phase II study on trabectedin in adults and young adults HEY1-NOCA2 positive skeletal and extra-skeletal mesenchymal chondrosarcoma (MCS) - ISG-MCS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Age = 16 years old, Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation each cycle of chemotherapy. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective method of birth control throughout the study and thereafter, at the end of study treatment, for 3 months in female patients of childbearing potential and for 5 months in men in fertile age, Cardiac ejection fraction =50% as measured by echocardiogram, No history of arterial and/or venous thromboembolic event within the previous 12 months, The patient or legal representative must be able to read and understand the informed consent form (ICF) and must have been willing to give written informed consent and any locally required authorisation before any study-specific procedures, including screening evaluations, sampling, and analyses., Histological centrally confirmed diagnosis of skeletal or extra-skeletal MCS with the documented presence of HEY1-NCOA2 fusion (a paraffin embedded tumour block is required for centralized review), Locally advanced disease (i.e. surgical resection of local disease unfeasible radically or unaccepted by the patient or amenable to become less demolitive or feasible or easier after cytoreduction) and/or metastatic disease, Measurable or evaluable disease with RECIST v1.1, Evidence of progression by RECIST v1.1 during the 6 months before study entry, Patients must be pre-treated with at least one prior chemotherapy treatment containing anthracyclines for the advanced phase of disease and with a maximum of 3 lines, Eastern Cooperative Oncology Group (ECOG) Performance Status = 2, Adequate bone marrow function (Blood transfusions to reach the baseline requested Hb level are not allowed), Adequate organ function
排除标准
- •Other primary malignancy with <5 years clinically assessed disease free interval, except basal cell skin cancer, cervical carcinoma in situ or other neoplasm judged to entail a low risk of relapse, Known brain metastasis, Known chronic liver disease (i.e. chronic active hepatitis and cirrhosis), Known diagnosis of human deficiency virus (HIV) infection, Active or chronic hepatitis B or C requiring treatment with antiviral therapy, Medical history of hemorrhage or a bleeding event = Grade 3 (NCI-CTCAE v 5.0) within 4 weeks prior to the initiation of study treatment, Evidence of any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject’s participation in the study or evaluation of the study results, Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs, Any other factors, that, at judgment of investigator, could affect the safety of the patients according to the available trabectedin safety data, Expected non-compliance to medical regimens, Previous treatment with radiation therapy within 14 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents previously administered, Previous radiotherapy to 25% of the bone marrow, Major surgery within 2 weeks prior to study entry, Participation in another clinical study with an investigational product, which last dose was taken less than 4 weeks prior to the start of the treatment., Persistent toxicities (= NCI CTCAE v5.0 grade 2) with the exception of alopecia, caused by previous anticancer therapies., Pregnancy or breast feeding, Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e. congestive heart failure, myocardial infarction within 6 months of study), Medical history of arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within 6 months prior to the initiation of study treatment
研究者
相似试验
进行中（未招募）
1 期
Clinical trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomasCTIS2023-509215-81-00Asoc Grupo Espanol De Investigacion En Sarcomas72
进行中（未招募）
1 期
A clinical study to assess the efficacy of Trabectedin in advanced retroperitoneal leiomyosarcoma and in liposarcomaEUCTR2012-005428-14-ITItalian Sarcoma Group95
进行中（未招募）
1 期
combination of trabectedin and olaparib in ovarian cancer, fallopian tubes and primary of peritoneum already resistant to standard platinum drugsplatinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneumMedDRA version: 21.1Level: LLTClassification code 10033131Term: Ovarian carcinomaSystem Organ Class: 100000004864EUCTR2018-000230-35-ITFONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS66
进行中（未招募）
1 期
Study on advanced rearranged Mesenchymal chondrosarcomaPatients with advanced, histological and molecularly (presence of the HEY1-NCOA2 fusion) centrally confirmed diagnosis of MCS, with an evidence of RECIST progression within the 6 months prior to starting the study treatment and pre-treated with anthracycline-based chemotherapyMedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 100000004864EUCTR2019-003733-41-ITITALIAN SARCOMA GROUP20
进行中（未招募）
1 期
A PHASE II CLINICAL STUDY, ON TRABECTEDIN IN COMBINATION WITH PPARg AGONIST PIOGLITAZONE IN PATIENTS WITH ROUND CELL MYXOID LIPOSARCOMAS OR DEDIFFERENTIATED G1 OR G2 LIPOSARCOMAS WITH STABLE DISEASE IN TREATMENT WITH TRABECTEDIN ALONE.Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluationMedDRA version: 20.0Level: SOCClassification code 10028395Term: Musculoskeletal and connective tissue disordersSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: HLTClassification code 10024628Term: Liposarcomas malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10073139Term: Round cell liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005626-29-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI10